Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Good And Bad News For Genzyme MS Drugs At NICE: Aubagio In; Lemtrada Out For Now

This article was originally published in The Pink Sheet Daily

Executive Summary

Genzyme had a mixed few days with its MS drugs at NICE, with Aubagio finally succeeding but Lemtrada struggling on the back of a tough benefit/risk profile.


Related Content

NICE’s Tecfidera Restrictions In MS Leave It Fighting For U.K. Market Share
NICE's Unrestricted MS Indication For Lemtrada Could Boost It Ahead Of Rivals
Biogen’s Tecfidera Hit At NICE By Data Shortage, Functional Unblinding
Sanofi Claims Genzyme With $20.1 Billion Upfront And CVRs


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts